Figure 1.1: Age-Standardized Prevalence of Diagnosed Diabetes per 100 Adult Population by State, 1994 and 2002
Diabetes Care Quality Improvement: A Resource Guide for State Action
This figure shows two maps of the United States, one from 1994 and the other from 2002. They compare prevalence of diagnosed diabetes by State. The prevalence rates measured are:
- < 4%
States less than 4 percent: Colorado, Hawaii, Idaho, Kentucky, Maine, Minnesota, Montana, North Dakota, Oklahoma, Oregon, South Dakota, Washington, Wisconsin, and Wyoming.
States with prevalence 4 to 4.9 percent: Alabama, Alaska, Arizona, Connecticut, Florida, Georgia, Indiana, Iowa, Kansas, Maryland, Massachusetts, Missouri, Nebraska, Nevada, New Jersey, New York, North Carolina, Ohio, Rhode Island, Utah, Vermont, Virginia, and West Virginia.
States with prevalence 5 to 5.9 percent: Arkansas, California, Delaware, Illinois, Michigan, New Hampshire, New Mexico, Pennsylvania, South Carolina, Tennessee, Texas; 6 percent or higher, Louisiana, and Mississippi.
States less than 4 percent: None
States with prevalence 4 to 4.9 percent: Alaska, Colorado, Minnesota, and Utah.
States with prevalence 5 to 5.9 percent: Connecticut, Hawaii, Idaho, Iowa, Massachusetts, Montana, Nebraska, Nevada, New Hampshire, North Dakota, Oregon, Rhode Island, South Dakota, Vermont, Washington, Wisconsin, Wyoming.
States with prevalence 6 percent or higher: Alabama, Arizona, Arkansas, California, Delaware, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Mississippi, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, and West Virginia.
Figure 1.2: Results of the Diabetes Prevention Program Study
This figure is a bar chart that compares the percent reduction in incidence of type 2 diabetes from diet/exercise, placebo, and Metformin. The results are as follows:
- Diet/exercise vs placebo: 58%
- Metformin vs placebo: 31%
- Diet/exercise vs Metformin: 39%
Source: Knowler et al., 2002. Randomized clinical trial with average 2.8-year follow-up period.